Hdac-in-4
Hdac-in-4 Uses, Dosage, Side Effects, Food Interaction and all others data.
Hdac-in-4 is under investigation in clinical trial NCT03873025 (A Study of Hdac-in-4 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-cell Lymphoma).
| Trade Name | Hdac-in-4 |
| Generic | CXD101 |
| CXD101 Other Names | Hdac inhibitor cxd101, Hdac-in-4 |
| Type | |
| Formula | C24H29N5O |
| Weight | Average: 403.53 Monoisotopic: 403.237210574 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Hdac-in-4
